First-In-Human Phase I Study Of Hpn424, A Tri-Specific Half-Life Extended Psma-Targeting T-Cell Engager In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要